Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581794 | 1.00 | AKR1C3 (0.43) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1582010 | 0.82 | AKR1C3 (0.43) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1582012 | 0.82 | AKR1C3 (0.43) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1582067 | 0.80 | MAPT (0.46) | AKR1C3ALDH1A1 | |
| SCHEMBL1582071 | 0.80 | MAPT (0.46) | AKR1C3ALDH1A1 | |
| SCHEMBL1582055 | 0.80 | AKR1C3 (0.41) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1582057 | 0.80 | AKR1C3 (0.41) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1581960 | 0.78 | AKR1C3 (0.47) | AKR1C3PTGS2ALDH1A1 | |
| SCHEMBL1581391 | 0.77 | KMT2A (0.44) | AKR1C3ALDH1A1 | |
| SCHEMBL1581394 | 0.77 | KMT2A (0.44) | AKR1C3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585739-B1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | LILLY CO ELI (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7576108-B2 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | ELI LILLY AND COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1585739-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063179-A1 | SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111353-A1 | Substituted arylcyclopropylacetamides as glucokinase activators | GCK, GCKR, GALK1 | AKR1C3 906/4885PTGS2 1483/4885ALDH1A1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.